Skip to main content

Table 3 Renal outcome trials completed in 2019: comparison of results vs. placebo

From: Report from the 5th cardiovascular outcome trial (CVOT) summit

CREDENCE [21]

Class and cardiovascular/renal endpoints

HR (95% CI) p-value

Event

Event rate (%) active vs. placebo group

Primary composite endpoint

 

Primary composite outcome

11.1 vs. 15.5

 End-stage kidney disease, sustained doubling of serum creatinine level, death from renal or CV disease

0.70 (0.59–0.82) p = 0.00001

  

Secondary outcome

 

Adverse events

Event rate (%) active vs. placebo group (p-value)

 CV death or hospitalization for heart failure

0.69 (0.57–0.83) p < 0.001

Renal event

3.9 vs. 4.5a (–)

Secondary outcome

 

Acute pancreatitis

0.2 vs. < 0.1 (–)

 CV death, myocardial infarction, or stroke

0.80 (0.67–0.95) p = 0.01

Diabetic ketoacidosis

0.5 vs. < 0.1 (–)

Secondary outcome

   

 Hospitalization for heart failure

0.61 (0.47–0.80) p < 0.001

Secondary outcome

 

 End-stage kidney disease, doubling of serum creatinine level, or renal death

0.66 (0.53–0.81) p < 0.001

Secondary outcome

 

 All-cause death

0.83 (0.68–1.02)

Secondary outcome

 

 CV death, myocardial infarction, stroke, or hospitalization for heart failure or for unstable angina

0.74 (0.63–0.86)

Secondary outcome

 

 Dialysis, kidney transplantation, or renal death

0.72 (0.54–0.97)

Exploratory outcome

 

 Cardiovascular death

0.78 (0.61–1.00) p = 0.05

Exploratory outcome

 

 Renal death

0.78 (0.61–1.00)

  1. aAcute kidney injury